Pangaea Data Awarded Strategic Partnership by Mersey Care NHS Foundation Trust and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC)

To characterize patients across hard-to-diagnose mental health conditions

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • Established by Mersey Care NHS Foundation Trust and the University of Liverpool, M-RIC is a bold and ambitious ‘learning system' funded through the UK Government's Office for Life Sciences and the National Institute for Health and Care Research, as part of the national ‘Mental Health Mission'.
  • Pangaea Data, (Pangaea), provider of a novel Artificial Intelligence (AI)-driven product for characterizing patients by automatically discovering clinical signatures for 4,000 hard-to-diagnose conditions in an evolving, privacy-preserving and scalable manner, today announced that it has been awarded a strategic partnership by the newly established Mental Health Research for Innovation Centre (M-RIC).
  • Driven by the NHS, M-RIC will create the infrastructure necessary for research and innovation, with a focus on under-researched and under-funded areas such as early intervention in psychosis, mood disorders, and children and young people's mental health.

Pangaea Data, (Pangaea), provider of a novel Artificial Intelligence (AI)-driven product for characterizing patients by automatically discovering clinical signatures for 4,000 hard-to-diagnose conditions in an evolving, privacy-preserving and scalable manner, today announced that it has been awarded a strategic partnership by the newly established Mental Health Research for Innovation Centre (M-RIC). M-RIC will be applying Pangaea’s product to characterize patients across hard-to-diagnose mental health conditions and discover new clinically actionable intelligence, which will help to find more undiagnosed, misdiagnosed and miscoded patients.

The aim of the partnership is to discover larger patient pools with high precision through Pangaea’s product, allowing M-RIC to improve screening success rates and recruit more suitable patients for clinical trials and care, who may otherwise be missed if searches were limited to metadata or generic natural language processing (NLP) based approaches. The discovery of new, clinically actionable signatures will improve clinicians’ knowledge of their patients’ journeys and enable them to select more appropriate clinical care pathways. Clinicians will also gain insights into new areas of research and development, which in turn opens additional opportunities to collaborate with external teams.

Pangaea’s product capabilities have been clinically proven to find 22 times more undiagnosed, miscoded and at-risk patients; match patients to five times more suitable clinical trials and therapies; discover new relationships between drugs, features and adverse events; predict prognosis; halve treatment costs; and save 90% in costs and time compared to manual and alternative NLP-based methods.

Established by Mersey Care NHS Foundation Trust and the University of Liverpool, M-RIC is a bold and ambitious ‘learning system’ funded through the UK Government’s Office for Life Sciences and the National Institute for Health and Care Research, as part of the national ‘Mental Health Mission’. Driven by the NHS, M-RIC will create the infrastructure necessary for research and innovation, with a focus on under-researched and under-funded areas such as early intervention in psychosis, mood disorders, and children and young people’s mental health.

Dr. Vibhor Gupta, Founder and Director at Pangaea, said: “We are excited to partner with Mersey Care NHS Foundation Trusts and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC). The application of Pangaea’s product in the context of mental health conditions is critical, for both patients and clinicians, to support preventative health and precision medicine.

Professor Nusrat Husain, Honorary Consultant Psychiatrist Early Intervention Service, and Director of Research and Innovation and Global Centre for Research on Mental Health Inequalities at Mersey Care NHS Foundation Trust, said: “The infrastructure that the M-RIC creates provides important opportunities to build upon our existing work to address mental health inequalities. Early detection and intervention are critical elements of our clinical practice at both individual and population level, providing a vital mechanism to improve access to mental health services, particularly within the underserved population. Through partnerships we have created, such as with Pangaea, we are provided the opportunity to speed up the early identification and treatment in a timely manner. This will not only positively benefit the people across Cheshire and Merseyside and beyond, but it will also create a blueprint replicable nationally and globally.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

"We are thrilled with the DEA's decision, which underscores the potential of MIRA-55 as a groundbreaking therapeutic candidate," said Erez Aminov, Chairman & CEO of MIRA Pharmaceuticals. "This ruling allows us to focus on MIRA-55's unique cognitive and anxiety benefits. With access to $90B traditional neurological and $30B cannabis markets, MIRA-55 represents a significant value proposition for our company.  We remain committed to advancing it through the development pipeline for treating these diseases from which so many currently suffer."

Abu Dhabi Issues First BioTech Inventor-Class Golden Visa to Catalyze “Made-In-Abu-Dhabi IP” to Rockefeller University Inventor Dr Kambiz Shekdar, PhD

Dr Kambiz Shekdar said: "I gratefully take this opportunity as my solemn commitment to help build up the BioTech sector in Abu Dhabi with the same home-grown can-do-and-have-done record of accomplishment demonstrated by Emirati leadership, its people, and nation, and to do so collegially with the best of the best of the world's human capital across frontier technologies who, like myself, are drawn to the UAE with the thirst to pioneer and build better like only possible in the red-hot entrepreneurial climate of the UAE."

Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups

"We celebrate the growing base of research and technological advances within the region's health and life sciences sector," said Chandra Briggman, President and CEO of Activation Capital.

By using this website you agree to accept Medical Device News Magazine Privacy Policy